Celine Wilke, MD

Celine Wilke,MD, holds nearly 20 years of pharmaceutical industry experience, most recently in radiopharmaceutical drug development. Her expertise in advancing precision oncology treatments from early development to regulatory approval has guided medical teams at global companies through the development and commercialization of their candidates. Dr. Wilke is the Chief Medical Officer at ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company.